Cargando…
Tirzepatide for type 2 diabetes
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium–glucose cotran...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioExcel Publishing Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470858/ https://www.ncbi.nlm.nih.gov/pubmed/37664792 http://dx.doi.org/10.7573/dic.2023-6-1 |